ATC codes:
L01XA01
EMLc
Indication
Other specified malignant neoplasms of the ovary
ICD11 code:
2D23.Y
INN
Cisplatin
Medicine type
Chemical agent
List type
Complementary
Formulations
Parenteral > General injections > IV:
50 mg per 50 mL ;
100 mg per 100 mL
Sex
All
Age
Also recommended for children
Therapeutic alternatives
The recommendation is for this specific medicine
Patent information
Patents have expired in most jurisdictions
Read more
about patents.
Summary of evidence and Expert Committee recommendations
Cisplatin was originally added to the EML in 1984 and to the EMLc in 2007. In 2009, cisplatin was replaced by carboplatin with a square box for treatment of advanced ovarian cancer.
In 2015, as part of the comprehensive review of cancer medicines undertaken by the Expert Committee, cisplatin was added to the complementary list of the EML and EMLc for use in treatment protocols for ovarian germ cell tumours. The relevant extract from TRS994 regarding the Expert Committee's 2015 consideration of treatment protocols for ovarian germ cell tumours is attached.